IBT.V - IBEX Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD

IBEX Technologies Inc.

5485 Pare Street
Suite 100
Montreal, QC H4P 1P7

Full Time Employees

Key Executives

Mr. Paul BaehrChairman, Chief Exec. Officer and Pres199.65kN/A74
Mr. Richard Collin CPA-CADirector of Fin. and Sec.140.03kN/AN/A
Mr. Claire BergeronVP of Admin.N/AN/AN/A
Ms. Catherine PoulinVP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. The company produces a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. It also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, the company provides lyophilization services related to the making of components for disposable medical devices, which are used in the hemostasis point of care market. IBEX Technologies Inc. offers its enzymes to manufacturers of medical devices, quality control labs, and academic research institutions. The company is based in Montreal, Canada.

Corporate Governance

IBEX Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.